ResearcherFudan UniversityActive in the last 2 years

Wei Jun Peng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5780-2157; OpenAlex author ID A5058810009. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 3

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tianfu Wen · 2 shared papers, 2019–2024 · strength 0.35
- Paper Molecular characterization and prognostic relevance of m6A regulators in pancreatic adenocarcinoma DOI 10.21203/rs.3.rs-4948418/v1 ↗
- Paper MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS. DOI 10.1016/j.biopha.2019.109424 ↗
Mei Liu · 1 shared paper, 2024 · strength 0.23
- Paper Molecular characterization and prognostic relevance of m6A regulators in pancreatic adenocarcinoma DOI 10.21203/rs.3.rs-4948418/v1 ↗
Chuan Li · 1 shared paper, 2024 · strength 0.23
- Paper Molecular characterization and prognostic relevance of m6A regulators in pancreatic adenocarcinoma DOI 10.21203/rs.3.rs-4948418/v1 ↗
Fei Xie · 1 shared paper, 2019 · strength 0.12
- Paper MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS. DOI 10.1016/j.biopha.2019.109424 ↗
Jie Liu · 1 shared paper, 2014 · strength 0.07
- Paper URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial-mesenchymal transition-driven invasion. DOI 10.1007/s12032-014-0064-y ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.